treatmentoptions4u.com

Rahika (Capmatinib) available Delhi, Mumbai, Madras, Hyderabad, Bangalore India

Rahika (Capmatinib) Tablet

Generic brands for Capmatinib Tablet Available in India Brand Name Rahika Generic Name Capmatinib Strength 150mg Manufacturer Novartis India Ltd

Category: , ,
Tags:

Description

Description

This page contains brief details about the drug capmatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Capmatinib is an anticancer drug that belongs to the class of medications called protein kinase inhibitors. FDA approved it initially in August 2020 for treating a certain type of lung cancer.

Mechanism of Action of Capmatinib

Capmatinib is a kinase inhibitor that targets mesenchymal-epithelial transition (MET). It works by blocking the action of this abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.

Uses of Capmatinib

Capmatinib is available as a tablet. It is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other body parts or is caused by a change (mutation) in a gene that makes an enzyme called MET in adults.

Capmatinib Dosage available

It is an orally available prescription drug. Your doctor will decide the dose and duration of capmatinib based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water.

We can ship to :

News/Updates

References

  1. Capmatinib Tablets, PIL.; 2022. Accessed May 2, 2023. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf
  2. TABRECTATM – Capmatinib Tablets.; 2020. Accessed May 2, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf
  3. Vansteenkiste JF, Van De Kerkhove C, Wauters E, Van Mol P. Capmatinib for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy. 2019;19(8):659-671. doi:https://doi.org/10.1080/14737140.2019.1643239
  4. Choi W, Park SY, Lee Y, et al. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. Cancer Research and Treatment. Published online January 29, 2021. doi:https://doi.org/10.4143/crt.2020.1331